VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q1 2021
Holdings as of Mar 31, 2021, filed May 14, 2021. Long positions only.
- Positions
- 28
- No 13F data for Q4 2020
- Portfolio value
- $921.8M
- No 13F data for Q4 2020
Livermore's 13F data starts with Q1 2021, so this quarter has no previous quarter to compare with and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| VRDNViridian Therapeutics, Inc. | COM | 19,495 | $326.0K | <0.1% | – | – | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 120,649 | $2.45M | 0.3% | – | – | History |
| SPRYARS Pharmaceuticals, Inc. | COM | 85,000 | $3.71M | 0.4% | – | – | History |
| MTCRMetacrine, Inc. | COM | 680,000 | $4.22M | 0.5% | – | – | History |
| BCTG Acquisition Corp05492W103 | COM | 500,000 | $5.56M | 0.6% | – | – | – |
| EYPTEyePoint, Inc. | COM NEW | 700,000 | $7.11M | 0.8% | – | – | History |
| ALGSAligos Therapeutics, Inc. | COM | 408,377 | $9.29M | 1.0% | – | – | History |
| COGTCogent Biosciences, Inc. | COM | 1,088,817 | $9.56M | 1.0% | – | – | History |
| APTOAptose Biosciences Inc. | COM NEW | 1,605,400 | $9.59M | 1.0% | – | – | History |
| ACETAdicet Bio, Inc. | COM | 1,000,000 | $13.1M | 1.4% | – | – | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 591,782 | $13.2M | 1.4% | – | – | History |
| KURAKura Oncology, Inc. | COM | 575,000 | $16.3M | 1.8% | – | – | History |
| EPIXESSA Pharma Inc. | COM NEW | 625,754 | $18.2M | 2.0% | – | – | History |
| KROSKeros Therapeutics, Inc. | COM | 372,306 | $22.9M | 2.5% | – | – | History |
| PHVSPharvaris N.V. | COM | 902,882 | $25.3M | 2.7% | – | – | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 1,240,610 | $25.6M | 2.8% | – | – | History |
| RLMDRelmada Therapeutics, Inc. | COM | 853,206 | $30.0M | 3.3% | – | – | History |
| LONALeonaBio, Inc. | COM | 1,691,623 | $31.1M | 3.4% | – | – | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 16,302,596 | $34.7M | 3.8% | – | – | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 2,641,809 | $40.9M | 4.4% | – | – | History |
| Trillium Therapeutics Inc.89620X506 | COM NEW | 4,040,000 | $43.4M | 4.7% | – | – | – |
| KNTEKinnate Biopharma Inc. | COM | 1,473,014 | $45.9M | 5.0% | – | – | History |
| CGEMCullinan Therapeutics, Inc. | COM | 1,176,145 | $49.0M | 5.3% | – | – | History |
| ALTAltimmune, Inc. | COM NEW | 3,500,000 | $49.5M | 5.4% | – | – | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 1,536,193 | $51.0M | 5.5% | – | – | History |
| ACRSAclaris Therapeutics, Inc. | COM | 3,720,582 | $93.8M | 10.2% | – | – | History |
| CNSTConstellation Pharmaceuticals Inc | COM | 4,016,873 | $94.0M | 10.2% | – | – | History |
| TILInstil Bio, Inc. | COM | 6,865,076 | $172.2M | 18.7% | – | – | History |